Human papillomavirus-associated anal and cervical neoplasia: evaluation of vaccino-prophylaxis programs
https://doi.org/10.21518/2079-701X-2018-7-12-17
Abstract
The review examines a role of HPV in the development of pre-cancer and cancer of the anogenital region. It presents the current data on the incidence of cervical (CIN) and anal intraepithelial neoplasia (AIN), the HPV infection of the anal region in women at risk (CIN, VIN, VaIN). Methods for the diagnosis of HPV-associated diseases of the anogenital region are considered. The article reviews the literature on the importance of AIN screening development in patients with CIN, VIN, VaIN. It also provides the results of own studies of HPV infection of the anal region in patients with cervical neoplasias, data on the HPV trophicity to the epithelium of the cervical canal and the anal region. Type 16 HPV is the dominant type of HPV in patients with CIN in the cervical canal and in the anus. HPV-associated cervical diseases, in particular CIN, create a risk of infection and development of HPV-associated diseases of the anal region, including AIN. A quadrivalent HPV vaccine is now available in Russia. Although initially created and used to protect against injuries to the cervix caused by HPV, it should also be considered for the prevention of other types of HPV-associated anogenital pre-cancer and cancer.
About the Authors
N. M. Nazarova
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia, Moscow
Russian Federation
MD
Russian Federation
MD
V. N. Prilepskaya
V.I. Kulakov National Medical Research Centre for Obstetrics, Gynaecology and Perinatology of the Ministry of Health of Russia, Moscow
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Schiffman M, Wentzensen N. From Human papillomavirus to cervical cancer. Obstet Gynecol, 2010, 116(1): 177-185.
2. Bosh FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst, 1995, 87: 796-802.
3. Walboomers JM, Jacobs MV, Manos MM et al. Humn papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 1999, 87: 796-802.
4. de Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11: 1048.
5. Bosh FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal realation between human papillomavirus and cervical cancer. J Clin Pathol, 2002, 55: 244-265.
6. Shiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. Vaccine, 2008, 26(suppl 10): K1-16.
7. http: //www.cancer.org/cancer/cervicalcancer/ detailedguide/cervical-cancer-key-statistics.
8. http: //www.cancer.org/cancer/analcancer/ detailedguide/anal-cancer-what-is-key-statistics.
9. Johnson LG, Madeleine MM, Newcomer LM, Schwartz SM, Daling JR. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer, 2004, 101(2): 281-288.
10. Cancer Statistics. Surveillance Epidemiology and End Results, National Cancer Institute. Available at: http: //www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/document/ acspc-036845.pdf. Retrieved October 22, 2013.
11. Munoz N, Bosh FX, Shah V et al. The Epidemiology of Cervical Cancer and Human Papillomavirus. Lyon, France: International Agency for Research on Cancer (WHO), 1992. IARC Scientific Publications No. 119.
12. Peng HQ, Liu SL, Mann V et al. HPV types 16 and 33, Herpes Simplex Type 2, and other risk factors in cervical cancer in Sichuan Province, China. Int J Cancer, 1991, 47: 711-716.
13. Jones CJ, Brinton LA, Hamman RF et al. Risk factors for in situ cervical cancer: results from a case-control study. Cancer Res, 1990, 50: 3657-3662.
14. Cuzick J, Terry G, Ho L et al. Type specific HPV DNA as predictor og high-grade cervical intraepithelial neoplasia. Br. J Cancer, 1994, 69: 167-171.
15. Koutsky LA, Holmes KK, Critchlow CW et al. Cohort study of risk of cervical intraepithelial neoplasia grade 2 or 3 assotiated with cervical papillomavirus intection. N Engl J Med, 1992, 327: 127-178.
16. Nobbenhuis M, Walboomers JM, Helmerhorst TL, Rozendaal L. Relation of human papillomavirus status to cervical lesions and consequens for cervical-cancer screening: a prospective study. Lancet, 1999, 354: 20.
17. Burk RD, Chen Z, Van Doorslaer K. Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics, 2009, 12(5-6): 281-290.
18. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int. J. Cancer, 2004, 111: 278-285.
19. Egawa K. Do human papillomaviruses target epidermal stem cells? Dermatology, 2003, 207: 251- 254.
20. Herfs M, Vargas SO, Yamamoto Y, Howitt BE, Nucci MR, Hornick JL, McKeon FD, Xian W, Crum CP. A novel blueprint for “top down” differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J. Pathol., 2013, 229: 460-468.
21. Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, Munger K, Feldman S,
22. McKeon FD, Xian W et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc. Natl. Acad. Sci. USA, 2012, 109: 10516-10521.
23. Schmitt A, Rochat A, Zeltner R, Borenstein L, Barrandon Y, Wettstein FO, Iftner T. The primary target cells of the high-risk cottontail rabbit pap-illomavirus colocalize with hair follicle stem cells. J. Virol., 1996, 70: 1912-1922.
24. Martens JE, Smedts FM, Ploeger D, Helmerhorst TJ, Ramaekers FC, Arends JW, Hopman AH. Distribution pattern and marker profile show two subpopulations of reserve cells in the endocervi-cal canal. Int. J. Gynecol. Pathol., 2009, 28: 381-388.
25. Valari O, Koliopoulos G, Karakitsos P, Valasoulis G, Founta C, Godevenos D et al. Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications. Gynecol Oncol, 2011, 122: 505-508.
26. Moscicki AB, Schiffman M, Kjaer S, Villa L. Chapter 5: Updating the natural history of HPV and ano-genital cancer. Vaccine, 2006, 24(suppl 3): 42-51.
27. Calore E, Giaccio C, Nadal S. Prevalence of anal cytologic abnormalities in women with positive cervical cytology. Diagn Cytopathol, 2011, 39: 323-327.
28. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J. Presumed previous human papillomavirus (HPV) related gynecologicalcancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol, 2009, 114: 395-398.
29. Santoso JT, Long M, Crigger M, Wan JY, Haefner HK. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol, 2010, 116: 578-582.
30. Chin-Hong PV, Vittinghoff E, Cranston RD et al. Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis, 2004, 190: 2070.
31. Machalek DA, Poynten M, Jin F et al. Anal human papillomavirus infection and assoicated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol, 2012, 13(5): 487-500.
32. Palefsky JM, Holly EA, Ralston ML et al. Anal cyto-logical abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med, 1997, 73: 174.
33. Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papilloma-virus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis, 1998, 177: 361.
34. Edgren G, Sparén P. Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study. Lancet Oncol, 2007, 8: 311-316.
35. Saleem AM, Paulus JK, Sharpter AP, Baxter NN, Roberts PL, Ricciardi R. Risks of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol, 2011, 117: 643-649.
36. Darragh TM, Birdsong GG, Luff RD, Davey DD. Anal-rectal cytology. In: Solomon D, Nayar R, eds. The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria and Explanatory Notes (2nd ed.). New York, NY: Springer, 2004: 169-175.
37. Darragh TM. Anal cytology. In: Wilbur DC, Henry MR, eds. College of American Pathologists Practical Guide to Gynecologic Cytopathology: Morphology, Management and Molecular Methods. Northfield, IL: CAP Press, 2008: 177-181.
38. Davey E, Barratt A, Irwig et al. Effect of study design and quality on unsatisfactory rates, cytology classifications, and accuracy in liquid-based versus conventional cervical cytology: a systematic review. Lancet, 2006, 376: 122-132.
39. Chiao EY, Giordano TP, Palefsky JM et al. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis, 2006, 43(2): 223-233.
40. Salit LE, Lytwyn A, Rabound J et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS, 2010, 24(9): 1307-1313.
41. Bean SM, Chhieng DC. Anal-rectal cytology: a review. Diagn Cytopathology, 2010, 38(7): 538-546.
42. Santoso JT, Long M, Crigger M, Wan JY, Haefner HK. Anal intraepithelial neoplasia in women with genital intraepithelial neoplasia. Obstet Gynecol, 2010, 116(3): 578-578.
43. Alemany L, Saunier M, Alvarado-Cabrero I. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer, 2014, 136: 98-107.
44. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a metaanalysis. Int J Cancer, 2009, 124: 1626-1636.
45. de Sanjose S, Quint WG, Alemany L et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol, 2010, 11: 1048-1056.
46. Li N, Franceschi S, Howell-Jones R et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer, 2011, 128: 927-935.
47. De Martel C, Ferlay J, Franceschi S et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol, 2012, 13: 607-615.
48. Nazarova NM, Burmenskaya OV, Sulamanidze LA, Prilepskaya VN, Pavlovich SV, Trofimov DYu. The prevalence of HPV types of the anogenital region in patients with HPV-associated cervical disease. Akusherstvo i Ginekologiya, 2015, 12: 89-96.
49. Doorbar J. Molecular biology of human papilloma-virus infection and cervical cancer. Clin Sci Lond, 2006, 110: 525-541.
50. Prophylaxis of cervical cancer. Edited by Sukhikh GT and Prilepskaya VN. 2012
51. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T et al. Populationlevel impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis, 2013, 15: 565-580.
52. Lehtinen M et al. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from rand-omized trials. BMJ Open, 2017, 7: e015867. doi:10.1136/bmjopen-2017-015867.
53. Machalek DA, Garland SM, Brotherton JML. Very low prevalence of vaccine human papillomavirus (HPV) types among 18 to 35 year old Australian women, nine years following implementation of vaccination. J Infect Dis, 2018 Feb 7. doi: 10.1093/ infdis/jiy075.
Review
For citations:
Nazarova NM, Prilepskaya VN. Human papillomavirus-associated anal and cervical neoplasia: evaluation of vaccino-prophylaxis programs. Meditsinskiy sovet = Medical Council. 2018;(7):12-17. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-12-17
Views:
1035
Email this article 